Hepatic amyloidosis: a prevalence study and clinical characterization of a rare and severe disease

• Emanuel Dias ^[1] ; Hélder Cardoso ^[1] ; Margarida Marques ^[1] ; Rodrigo Liberal ^[1] ; Susana Lopes ^[1] ; Pedro Pereira ^[1] ; João Santos-Antunes ^[1] ; Jorge Pinheiro ^[1] ; Joanne Lopes ^[1] ; Fátima Carneiro ^[1] ; Guilherme Macedo ^[1]
  1. [1] Centro Hospitalar Universitário de São João. Porto, Portugal
• Localización: Revista Española de Enfermedades Digestivas, ISSN-e 2340-4167, ISSN 1130-0108, Vol. 115, Nº. 1, 2023, págs. 16-21
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background and aim: Amyloidosis is a systemic disease characterized by extracellular deposition of amyloid protein, most commonly in the heart and kidney. Hepatic amyloidosis is a rare form of presentation that ranges from mild hepatomegaly and altered liver biochemical tests to acute liver failure. The aims of this study were to evaluate the prevalence of amyloidosis in patients undergoing liver biopsy and describe its main clinical characteristics and prognostic impact. Methods: A retrospective analysis of all patients with a histological diagnosis of hepatic amyloidosis between January 2010 and December 2019 was performed. Major results: A total of 7 patients were identified from a total of 1773 liver biopsy procedures (0.4%), with a female predominance (6/7) and median age of diagnosis of 62 years. The most common clinical manifestations included hepatomegaly (4/7), jaundice (2/7) and peripheral edema (2/7), whereas 3/7 patients were asymptomatic. Every patient presented abnormalities in liver biochemical tests, more commonly cholestasis (6/7), but also cytolysis (4/7) or hyperbilirubinemia (2/7). Abnormal imaging findings included hepatomegaly, steatosis or parenchymal heterogeneity. In most patients (5/7), other organs were involved, most commonly with nephrotic syndrome (3/7) and infiltrative cardiomyopathy (3/7). The most common type was AA amyloidosis (3/7) followed by AL amyloidosis (2/7). The 1-year mortality rate was 43% and the median survival was 24 months. Conclusions: We report a low prevalence (0.4%) of amyloidosis among patients undergoing liver biopsy. Although rare, hepatic amyloidosis is associated with a dismal prognosis and a high index of suspicion is crucial to achieve an early diagnosis.